SYLENTIS
- Company typePrivate
- Founded2006
- HeadquartersMadrid, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
SYLENTIS firmographics
Firmographics- Name
- SYLENTIS
- Legal name
- Sylentis, S.A., Sociedad Unipersonal
- Website
- https://sylentis.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SYLENTIS industry classification
Industry- Product category
- RNAi-based Ophthalmic Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where SYLENTIS is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
SYLENTIS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Drug Development and Licensing: Developing proprietary RNAi-based drugs for ophthalmological diseases. Revenue generated through licensing agreements, co-development deals, and eventual product commercialization. Currently has products in Phase III (tivanisiran) and Phase II (SYL1801) clinical trials.
- CDMO Services: Provides specific and customized services for development of RNAi-based compounds for a wide range of targets and oligonucleotide-based drug development for new or existing therapies. Services offered to pharmaceutical and biopharmaceutical companies.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
SYLENTIS product offering
Product offeringCore offering
Sylentis is a clinical-stage biopharmaceutical company that develops siRNA-based ophthalmic drugs using RNA interference (RNAi) gene silencing technology. Its core pipeline comprises Tivanisiran (SYL1001) eye drops in Phase III for dry eye disease and SYL1801 in Phase II for wet age-related macular degeneration. The company also offers proprietary SirFinder™ AI software for siRNA design and CDMO services for oligonucleotide manufacturing to third-party pharma and biotech clients.
Product overview
Sylentis is a biopharmaceutical company specializing in ocular gene silencing using RNAi technology. The core offering consists of SirFinder™, an AI-powered siRNA design platform that enables rapid drug discovery, complemented by a pipeline of siRNA-based therapeutics. The product portfolio includes Tivanisiran (SYL1001) for dry eye disease in Phase 3, SYL1801 for age-related macular degeneration in Phase 2, and earlier-stage candidates for ocular allergies and retinitis pigmentosa. The company also offers CDMO services for oligonucleotide manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Tivanisiran (SYL1001) A small interfering RNA (siRNA) administered as eye drops for the treatment of Dry Eye Disease. Inhibits the synthesis of Transient Receptor Potential Vanilloid-1 (TRPV1), targeting both ocular pain detection and innate inflammatory response. Currently in Phase III clinical development.
- SYL1801 A chemically modified siRNA administered as eye drops for the prevention and control of wet age-related macular degeneration (AMD). Targets Nrarp to control neovascularization in the retina, offering a non-invasive alternative to intravitreal injections. Currently in Phase II clinical development.
- SirFinder™ Proprietary AI-based software platform that designs siRNA compounds using mathematical algorithms, neural networks, SVM, and machine learning to identify appropriate mRNA sequences with high silencing efficiency and specificity. Reduces candidate screening work from several years to just weeks. Offered for licensing and as part of partnership engagements.
- CDMO Services Contract Development and Manufacturing Organization services for RNAi-based compound development and oligonucleotide-based drug development for new or existing therapies. Provides customized services for pharmaceutical and biopharmaceutical companies seeking siRNA development and GMP manufacturing expertise.
Quantifiable outcome
- Phase III HELIX trial showed improvement (p=0.035) in reduction of central corneal staining for dry eye disease treatment
- +3 more outcomes
Companies that use SYLENTIS
Customer profileSegments3 records
Ideal customer profiles1 record
SYLENTIS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
SYLENTIS partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- IPCEI Med4Cure ConsortiumcoreSYOLIGO project is part of IPCEI Med4Cure approved on May 28, 2024, comprising 14 sub-projects led by 13 companies and 11 associated partners from Belgium, Spain, France, Italy, and others, plus 175 indirect partners. Sylentis is the only Spanish company selected as direct participant. Project focuses on sustainable development and manufacturing of RNA-based therapies for rare diseases in Spain and Europe.
- OLIGOFASTX ConsortiumcoreMultidisciplinary consortium comprising Sylentis (PharmaMar Group), Nanovex (Química del Nalón Industrial Group), and five SMEs (AptusBiotech, AptaTargets, Arthex, Nostrum Biodiscovery, Biotechnology Development for Industry in Pharmaceutical). Creates a comprehensive platform for accelerated development of oligonucleotide-based therapies in Spain. Funded by CDTI with €5.4 million.
- MAAVi Innovation Center (Kimitec)minorCollaboration with MAAVi Innovation Center to develop natural interference RNA molecules for pest and disease control to improve crop yield. Contributes revolutionary science to agriculture sector applications of RNAi technology.
- SECREted Project PartnersminorProject exploiting Synthetic and Systems Biology tools and aquatic biotechnology for developing new hybrid compounds for agrochemical, pharmaceutical, cosmetic and chemical sectors. Reverse-engineers biosynthetic pathways of extremophile and marine microorganisms.
- AgrarIA ConsortiumminorConsortium of 23 public-private organizations investigating Artificial Intelligence as backbone technology for transformation of Spanish agri-food sector value chain. Funded by Ministry of Digital Transformation and European Union NextGenerationEU.
- Academic and Research InstitutionsminorNetwork of collaborators including research centers, national and international universities along with public or private centers for drug development. Supports the company's interdisciplinary approach to RNAi therapeutics research.
Scale indicators7 records
Recent moves7 records
SYLENTIS competitors and assessment
Company assessmentDirect peers
- ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer® RNA editing technology for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Most directly comparable peer — also a mid-sized European-listed company using RNA-based approaches exclusively targeting ophthalmology indications.
Broad incumbents
- Arrowhead Pharmaceuticals: Larger, NASDAQ-listed siRNA platform company with a broad pipeline including ophthalmology candidates (e.g., ARO-LPA, ARO-C3). Comparable to Sylentis as a siRNA-based therapeutic developer, though substantially larger and more diversified across therapeutic areas.
- Alnylam Pharmaceuticals: The leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). Has granted Sylentis a technology option license, indicating direct engagement with Sylentis's platform and providing an incumbent benchmark for siRNA commercialization.
- Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved products. A broader RNA-targeting incumbent with adjacent (not identical) technology to Sylentis's siRNA approach and a similar emphasis on rare and ophthalmology indications.
Emerging players
- Arcturus Therapeutics: Clinical-stage RNA medicines company developing mRNA, siRNA, and LUNAR® delivery platforms. Comparable as a mid-cap RNA therapeutics developer pursuing ophthalmology and rare disease applications alongside vaccine programs.
- Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM® platform for stereopure oligonucleotide design. Comparable to Sylentis as a smaller-cap RNA therapeutics developer targeting rare genetic diseases, including ophthalmology indications.
- SparingVision: European clinical-stage ophthalmology gene therapy company focused on retinal diseases including retinitis pigmentosa. Comparable to Sylentis as a Europe-based, mid-sized biotech developing novel genetic medicines for inherited retinal disorders.
- Phio Pharmaceuticals: Clinical-stage RNAi-based immuno-oncology therapeutics developer using self-delivering RNAi (sd-rxRNA®) platform. Comparable to Sylentis as a small-cap RNAi platform company, though focused on oncology rather than ophthalmology.
- Ascidian Therapeutics: Early-stage RNA editing company developing therapies for neurological, neuromuscular, and ophthalmology diseases including Stargardt disease. Comparable to Sylentis as a next-generation RNA therapeutics company with explicit ophthalmology focus.
Others
- Nitto Denko Avecia: Leading oligonucleotide CDMO providing contract manufacturing and development services for RNA-based therapeutics including siRNA. Comparable to Sylentis's CDMO service line as an established commercial-scale oligonucleotide manufacturing competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SYLENTIS social profiles
Digital presenceSYLENTIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
SYLENTIS leadership team
Management profileNumber of profiles
Profiles7 records
SYLENTIS funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SYLENTIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SYLENTIS
What does SYLENTIS do?
Sylentis is a clinical-stage biopharmaceutical company that develops siRNA-based ophthalmic drugs using RNA interference (RNAi) gene silencing technology. Its core pipeline comprises Tivanisiran (SYL1001) eye drops in Phase III for dry eye disease and SYL1801 in Phase II for wet age-related macular degeneration. The company also offers proprietary SirFinder™ AI software for siRNA design and CDMO services for oligonucleotide manufacturing to third-party pharma and biotech clients.
Is SYLENTIS a public or private company?
SYLENTIS is a private company. It is classified as corporate owned and is currently operating.
When was SYLENTIS founded?
SYLENTIS was founded in 2006. It employs 11 to 50 people.
Where is SYLENTIS based?
SYLENTIS is headquartered in Madrid, Spain, in the Europe region.
How does SYLENTIS make money?
Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are CDMO Services.
Who are SYLENTIS's main competitors?
ProQR Therapeutics is listed as a direct peer. Broad incumbents are Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Emerging players are Arcturus Therapeutics, Wave Life Sciences, SparingVision, Phio Pharmaceuticals and Ascidian Therapeutics. Nitto Denko Avecia is listed as an others.
Does SYLENTIS have an API?
No public API is recorded for SYLENTIS.
What industry is SYLENTIS in?
SYLENTIS's product category is RNAi-based Ophthalmic Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.